Fig. 5From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from ChinaCA125 in patients with different BRCA status in multi-line therapy group. Note: There were four patients with BRCA mutant, one patient with BRCA suspected pathological mutation and also one patient with BRCA unknown clinical significance mutation in this groupBack to article page